(Q28222347)

9

0 references

Javed Butler

4

object named as

Javed Butler

0 references

Jacques Cornuz

2

object named as

Jacques Cornuz

0 references

Fred Paccaud

7

object named as

Fred Paccaud

0 references

author name string

Nicolas Rodondi

1

0 references

Pedro Marques-Vidal

3

0 references

Daniel Hayoz

5

0 references

Alain Pécoud

Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials

6

0 references

language of work or name

English

0 references

publication date

February 2008

0 references

published in

Preventive Medicine

0 references

volume

46

0 references

issue

2

0 references

page(s)

137-44

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2007.08.006

Why don't physicians follow clinical practice guidelines? A framework for improvement

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2007.08.006

Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2007.08.006

Improving aspirin prophylaxis in a primary care diabetic population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2007.08.006

Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2007.08.006

Incidence of first–ever ischemic stroke in the Canton Basle–City, Switzerland

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2007.08.006

Primary prevention of coronary heart disease: integrating risk assessment with intervention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2007.08.006

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2007.08.006

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2007.08.006

Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2007.08.006

Prevalence of asthma, aspirin intolerance, nasal polyposis and chronic obstructive pulmonary disease in a population-based study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2007.08.006

Framingham risk function overestimates risk of coronary heart disease in men and women from Germany—results from the MONICA Augsburg and the PROCAM cohorts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2007.08.006

Cardiovascular disease risk reduction in the Behavioral Risk Factor Surveillance System

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2007.08.006

Clinical practice. Aspirin for primary prevention of coronary events

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2007.08.006

Predictive value for the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese Multi-Provincial Cohort Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2007.08.006

Priorities among effective clinical preventive services: results of a systematic review and analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2007.08.006

Aspirin overprescription in primary cardiovascular prevention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2007.08.006

An adaptation of the Framingham coronary heart disease risk function to European Mediterranean areas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2007.08.006

Cardiovascular disease prevention practices by U.S. Physicians for patients with diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2007.08.006

Appropriate use of antiplatelets: is prescription in daily practice influenced by the global cardiovascular risk?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2007.08.006

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2007.08.006

AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2007.08.006

Aspirin use among adults with diabetes: recent trends and emerging sex disparities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2007.08.006

Final report on the aspirin component of the ongoing Physicians' Health Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2007.08.006

Aspirin use among adults aged 40 and older in the United States: results of a national survey

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2007.08.006

Variation in local policies and guidelines for cholesterol management: national survey

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2007.08.006

C-reactive protein levels and outcomes after statin therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2007.08.006

Assessing the risk/benefit profile before recommending aspirin for the primary prevention of cardiovascular events

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2007.08.006

Aspirin use for the primary prevention of coronary heart disease in older adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2007.08.006

Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2007.08.006

Aspirin use is low among United States outpatients with coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2007.08.006

Underutilization of aspirin persists in US ambulatory care for the secondary and primary prevention of cardiovascular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2007.08.006

Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA project populations. Monitoring trends and determinants in cardiovascular disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2007.08.006

Aspirin for the primary prevention of cardiovascular events: recommendation and rationale

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2007.08.006

The relation between blood pressure and mortality due to coronary heart disease among men in different parts of the world. Seven Countries Study Research Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2007.08.006

Serum total cholesterol and long-term coronary heart disease mortality in different cultures. Twenty-five-year follow-up of the seven countries study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2007.08.006

Prediction of Coronary Heart Disease Using Risk Factor Categories

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2007.08.006